MedTrace Logo

Severe Alcohol-use Disorder: a tDCS and Response Inhibition Training Intervention

NCT03447054 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 136

Last updated 2020-11-04

No results posted yet for this study

Summary

Most severe forms of alcohol-use disorder are thought to reflect an abnormal interplay between two neural systems: an overly active impulsive one driven by immediate rewards prospects and a weak reflective one, tuned on long-term prospects. The investigators propose that two non-pharmacological interventions, Transcranial Direct Current Stimulation (tDCS) and Inhibitory Control Techniques (ICT) may act on both systems when combined, which might ultimately result is a reduction of alcohol relapse rate.

Conditions

Interventions

BEHAVIORAL

Combined TDCS active and ICT active

Five 20-minute long sessions including TDCS (2 MicroAmperes during 20 minutes) and ICT, 5 consecutive days

BEHAVIORAL

Combined TDCS sham and ICT active

Five 20-minute long sessions including TDCS sham (non active) and ICT, 5 consecutive days

BEHAVIORAL

Combined TDCS active and ICT inactive

Five 20-minute long sessions including TDCS sham and no-cue inhibition training, 5 consecutive days

BEHAVIORAL

Combined Sham TDCS and inactive ICT

Five 20-minute long sessions including TDCS and no-cue inhibition training, 5 consecutive days

Sponsors & Collaborators

  • University Ghent

    collaborator OTHER

  • Université Libre de Bruxelles

    collaborator OTHER

  • Brugmann University Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2020-03-18
Completion
2020-09-01

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03447054 on ClinicalTrials.gov